![James Geraghty](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
James Geraghty
Vorsitzender bei
JUNIPER PHARMACEUTICALS INC
Vermögen: 1 Mio $ am 31.05.2026
Profil
Mr. James A. Geraghty is an Independent Non-Executive Director at CANbridge Pharmaceuticals Inc., a Chairman at Orchard Therapeutics (Europe) Ltd., an Independent Non-Executive Director at CANbridge Life Sciences Ltd., an Independent Director at Fulcrum Therapeutics, Inc., an Independent Director at Voyager Therapeutics, Inc. and a Chairman at Catalent JNP, Inc. He is on the Board of Directors at CANbridge Pharmaceuticals Inc., CANbridge Life Sciences Ltd., Fulcrum Therapeutics, Inc., Voyager Therapeutics, Inc., Bio Ventures for Global Health and Therapeutic Human Polyclonals, Inc. Mr. Geraghty was previously employed as a Chairman by OMass Therapeutics Ltd., a Chairman by Orchard Therapeutics Plc, a Chairman by Pieris Pharmaceuticals, Inc., a Chairman by Juniper Pharmaceuticals, Inc., a Senior Vice President by Third Rock Ventures LLC, a Senior VP-Strategy & Business Development by Sanofi, a President by Sanofi BV, a Chairman, President & Chief Executive Officer by rEVO Biologics, Inc., a Senior Vice President-International Development by Genzyme Corp., a Vice President-Marketing & Strategic Planning by Caremark International, Inc., and a Trustee by Joslin Diabetes Center, Inc. He also served on the board at ImmuneXcite, Inc., Idera Pharmaceuticals, Inc., Aceragen, Inc. and Genetix Biotherapeutics, Inc. He received his undergraduate degree from Georgetown University, a graduate degree from Yale Law School and a graduate degree from the University of Pennsylvania.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2026 | 90.714 ( 0,14 % ) | 627 741 $ | 31.05.2026 | |
| 31.03.2026 | 70.588 ( 0,12 % ) | 273 176 $ | 31.05.2026 | |
| 12.01.2026 | 700.000 ( 0,12 % ) | 181 307 $ | 31.05.2026 |
Aktive Positionen von James Geraghty
| Unternehmen | Position | Beginn |
|---|---|---|
| VOYAGER THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.01.2014 |
| FULCRUM THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 19.07.2016 |
| JUNIPER PHARMACEUTICALS INC | Vorsitzender | - |
| CANBRIDGE PHARMACEUTICALS INC. | Direktor/Vorstandsmitglied | 18.07.2018 |
CANbridge Life Sciences Ltd.
 CANbridge Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Produces biopharmaceutical products | Direktor/Vorstandsmitglied | 01.05.2017 |
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Researches on transformative gene therapies | Vorsitzender | 29.06.2018 |
Bio Ventures for Global Health
 Bio Ventures for Global Health Bio Ventures for Global Health is an organization focused on leveraging biotechnology to address global health challenges. The non-profit company is based in Washington, DC. It collaborates with various stakeholders to develop innovative solutions for diseases that disproportionately affect low-resource settings. Through strategic partnerships and initiatives, the company aims to improve health outcomes and access to healthcare in underserved communities worldwide. The CEO of the company is James C. Greenwood. | Direktor/Vorstandsmitglied | 12.10.2010 |
Therapeutic Human Polyclonals, Inc.
 Therapeutic Human Polyclonals, Inc. Pharmaceuticals: MajorHealth Technology Develops human antibody therapeutics | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von James Geraghty
| Unternehmen | Position | Ende |
|---|---|---|
OMass Therapeutics Ltd.
 OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Develops native mass spectrometry platform | Vorsitzender | 28.01.2026 |
| ░░░░░░ ░░░░░░░░░░░░░░░ | ░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von James Geraghty
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
80
Beziehungen ersten Grades
25
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 25 |
|---|---|
Catalent JNP, Inc.
 Catalent JNP, Inc. Miscellaneous Commercial ServicesCommercial Services Specializes in research and development of drugs & therapeutics | Commercial Services |
Caremark International, Inc.
 Caremark International, Inc. Medical/Nursing ServicesHealth Services Provides home healthcare services | Health Services |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Sanofi
 Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
ImmuneXcite, Inc.
 ImmuneXcite, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which develops monoclonal antibodies for cancer | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
bluebird bio, Inc.
 bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
Georgetown University
 Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bio Ventures for Global Health
Bio Ventures for Global Health Bio Ventures for Global Health is an organization focused on leveraging biotechnology to address global health challenges. The non-profit company is based in Washington, DC. It collaborates with various stakeholders to develop innovative solutions for diseases that disproportionately affect low-resource settings. Through strategic partnerships and initiatives, the company aims to improve health outcomes and access to healthcare in underserved communities worldwide. The CEO of the company is James C. Greenwood. | |
Therapeutic Human Polyclonals, Inc.
Therapeutic Human Polyclonals, Inc. Pharmaceuticals: MajorHealth Technology Develops human antibody therapeutics | Health Technology |
Joslin Diabetes Center, Inc.
 Joslin Diabetes Center, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for diabetes | Health Technology |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm targets companies operating in the fields of the healthcare sector. It provides financing for early stage capital requirements. It acts as a lead investor. | Finance |
Genzyme Europe BV
 Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical & biotherapeutic products | Health Technology |
rEVO Biologics, Inc.
 rEVO Biologics, Inc. BiotechnologyHealth Technology Develops and commercializes specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions | Health Technology |
Yale Law School
 Yale Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Voyager Therapeutics, Inc.
 Voyager Therapeutics, Inc. BiotechnologyHealth Technology Develops gene therapies for fatal and debilitating diseases of the central nervous system | Health Technology |
CANbridge Life Sciences Ltd.
CANbridge Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Produces biopharmaceutical products | Health Technology |
Pieris Pharmaceuticals, Inc.
 Pieris Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and markets an anticalin-brand protein technology | Health Technology |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Researches on transformative gene therapies | Health Technology |
Fulcrum Therapeutics, Inc.
 Fulcrum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines for patients by transforming gene regulation in disease | Health Technology |
OMass Therapeutics Ltd.
OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Develops native mass spectrometry platform | Commercial Services |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc BiotechnologyHealth Technology Engages in research and advancements of gene therapy to develop potential cures for genetic & other severe diseases | Health Technology |
CANbridge Pharmaceuticals Inc.
 CANbridge Pharmaceuticals Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Aceragen, Inc.
 Aceragen, Inc. BiotechnologyHealth Technology Discovers, develops, and commercializes therapeutics for oncology and rare diseases | Health Technology |
